The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Oroxine 150 microgram tablets



Aspen Pharma Trading LimitedPA1691/013/006

Main Information

Trade NameOroxine 150 microgram tablets
Active SubstancesLevothyroxine
Dosage FormTablet
Licence HolderAspen Pharma Trading Limited
Licence NumberPA1691/013/006

Group Information

ATC CodeH03AA Thyroid hormones
H03AA01 levothyroxine sodium

Status

License statusAuthorised
Licence Issued12/09/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back